Nelson Advisors have researched 20 future Healthtech and MedTech leaders in 20 European countries, highlighting the founders, scientists and technologists building innovative solutions and companies. In addition to the 20 x 20 Series, we have also predicted 3 HealthTech and MedTech hubs across Europe with the potential to become centres of excellence.

The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital in